Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.52 |
| ▸ | ANPEP | P15144 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | PEPD | P12955 | 2/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.30 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15130169 | 0.89 | MMP2 (0.39) | MMP2ANPEPALDH1A1PEPDFKBP1A | |
| SCHEMBL5633357 | 0.86 | ATM (0.49) | MMP2ANPEPATM | |
| SCHEMBL7456999 | 0.85 | P2RX3 (0.40) | MMP2ANPEPALDH1A1 | |
| SCHEMBL142967 | 0.85 | P2RX3 (0.40) | MMP2ANPEPALDH1A1 | |
| SCHEMBL18577311 | 0.85 | P2RX3 (0.40) | MMP2ANPEPALDH1A1 | |
| SCHEMBL24826391 | 0.85 | P2RX3 (0.40) | MMP2ANPEPALDH1A1 | |
| SCHEMBL1269514 | 0.85 | P2RX3 (0.40) | MMP2ANPEPALDH1A1 | |
| SCHEMBL2387781 | 0.85 | P2RX3 (0.40) | MMP2ANPEPALDH1A1 | |
| SCHEMBL1269513 | 0.85 | P2RX3 (0.40) | MMP2ANPEPALDH1A1 | |
| SCHEMBL6624196 | 0.85 | P2RX3 (0.40) | MMP2ANPEPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | MMP2 3959/4885ANPEP 4746/4885ALDH1A1 2731/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | MMP2 3985/4885ANPEP 4766/4885ALDH1A1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.